New drug cocktail shows promise for Tough-to-Treat throat cancer
NCT ID NCT05807880
First seen Jan 30, 2026 · Last updated Jun 05, 2026 · Updated 24 times
Summary
This study tests a combination of three drugs (anlotinib, penpulimab, and capecitabine) as a first treatment for people whose nasopharyngeal cancer has spread or come back. About 59 adults aged 18-65 with measurable tumors will receive the therapy. The goal is to see how long the cancer stays under control and how well patients respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.